Demographic data, disease background, and other clinical information by treatment group (intention to treat population, n=520)
| Tegaserod (n=259) | Placebo (n=261) | |
|---|---|---|
| Sex (n (%)) | ||
| Male | 33 (12.7) | 29 (11.1) |
| Female | 226 (87.3) | 232 (88.9) |
| Race (n (%)) | ||
| Caucasian | 42 (16.2) | 43 (16.5) |
| Chinese | 88 (34.0) | 88 (33.7) |
| Indian | 4 (1.5) | 7 (2.7) |
| Indonesian | 4 (1.5) | 2 (0.8) |
| Korean | 71 (27.4) | 68 (26.1) |
| Malaysian | 11 (4.2) | 9 (3.4) |
| Philippines | 8 (3.1) | 9 (3.4) |
| Thai | 30 (11.6) | 32 (12.3) |
| Other | 1 (0.4) | 3 (1.1) |
| Age (y) | ||
| Mean (SD) | 35.9 (12.4) | 36.0 (12.4) |
| Median | 35.0 | 33.0 |
| Weight (kg) | ||
| Mean (SD) | 57.6 (9.2) | 57.7 (10.7) |
| Median | 56.0 | 55.6 |
| Duration of IBS symptoms (months) | ||
| Mean (SD) | 86.3 (77.0) | 96.5 (96.8) |
| Median | 60.0 | 63.0 |